MINNEAPOLIS, July 18, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, announced today it has received a letter of determination from The Nasdaq Stock Market (“NASDAQ”) confirming that the Company has regained compliance with Listing Rule 5550(b)(1) requiring a minimum shareholders’ equity of $2.5 million. The determination was received from NASDAQ after the Company reported the completion of the sale of 5,200,000 shares of the Company’s common stock pursuant to an underwritten public offering. Urologix remains subject to the NASDAQ continued listing requirements.
